A landmark study funded by the National Institutes of Health (NIH) has revealed a previously unknown molecular mechanism that may explain how chronic gut inflammation significantly raises the risk of colorectal cancer — even after the inflammation has resolved. Published in the journal Nature in 2026, the findings from researchers at the Broad Institute of MIT and Harvard could fundamentally change how physicians assess long-term cancer risk in patients with inflammatory bowel conditions.
The Hidden Legacy of Gut Inflammation
Colorectal cancer is the third most commonly diagnosed cancer in the United States, and people living with conditions like ulcerative colitis or Crohn’s disease have long been known to face a higher risk. However, the precise biological mechanism connecting chronic gut inflammation to cancer development has remained elusive — until now.
The new research demonstrates that repeated cycles of gut inflammation leave what scientists describe as “epigenetic memories” in the colon’s stem cells. These molecular imprints persist for more than 100 days after inflammation ceases, quietly priming the tissue for accelerated tumor growth if cancer-causing mutations later arise.
“By spelling out how repeated cycles of injury in the gut may influence colorectal cancer risk, the authors have potentially opened avenues toward much-needed methods of early evaluation and therapy for a condition that is of increasing concern,” said Anthony Letai, M.D., Ph.D., director of NIH’s National Cancer Institute.
What Is Epigenetic Memory?
To understand this discovery, it helps to distinguish between the genome and the epigenome. While an individual’s DNA sequence generally remains fixed throughout life, the epigenome — a collection of chemical tags and annotations layered on top of the genome — is dynamic and responsive to environmental stressors.
Think of DNA as the hardware of a computer. The epigenome, then, is more like the software: it can be rewritten by experiences, such as infections, diet, toxins, or, as this study demonstrates, prolonged inflammation. These epigenetic changes regulate which genes are turned on or off, allowing cells to adapt to changing conditions.
In healthy tissue, this flexibility is beneficial — it helps cells recover after injury. But research suggests that in some circumstances, these adaptations can backfire. The epigenome “remembers” past damage in a way that can inadvertently prime cells for cancer development, even after the original inflammatory trigger is gone.
What the Research Found
The Broad Institute team simulated chronic colitis — a common form of intestinal inflammation — in mice, then tracked what happened to colon cells during and after the inflammatory episode. Using cutting-edge single-cell analysis, the researchers examined more than 52,000 individual cells to map how epigenetic changes unfolded.
Their key finding centered on a group of proteins called AP-1 transcription factors, which are known to govern how cells respond to stress and injury. The chronic colitis led to epigenetic alterations in colonic stem cells that ramped up AP-1 activity — and these alterations were heritable, meaning that as the stem cells divided and produced new daughter cells, they passed along this “activated” state.
Critically, this altered epigenetic state persisted for over 100 days after the inflammation had been removed — well beyond the visible signs of injury or disease. To test whether this had real-world cancer implications, the researchers then introduced tumor-promoting genes into two groups of mice: those who had recovered from chronic colitis, and those who had never experienced it.
The result was striking. Colorectal tumor growth was far more rapid in the colitis-recovered animals. When the researchers chemically blocked AP-1 activity, this accelerated tumor growth disappeared — strongly implicating AP-1 as the central molecular bridge between past inflammation and future cancer risk.
“We have known for some time that colitis can accelerate tumor growth after cancer has already begun, but here we show that the effect of chronic inflammation on cancer risk remains well after animals have recuperated,” said Jason Buenrostro, Ph.D., corresponding author and professor at Harvard University.
Implications for Colorectal Cancer Prevention and Screening
If this mechanism translates to humans — a hypothesis that the researchers believe is plausible but has yet to be confirmed in clinical trials — the implications for preventive medicine could be significant.
Currently, colorectal cancer screening guidelines for inflammatory bowel disease (IBD) patients often focus on the active presence of inflammation. But this study raises the possibility that the history of inflammation may matter just as much as its current status. A patient whose colitis has been in remission for years may still carry elevated cancer risk encoded in their gut stem cells.
The researchers suggest that tests capable of detecting these AP-1-related epigenetic signatures could one day serve as early-warning biomarkers, helping clinicians identify high-risk individuals before tumors form. Therapeutics designed to disrupt the post-colitis AP-1 activity described in this study may also represent a future strategy for stalling cancer development.
What This Means for People With Inflammatory Gut Conditions
For the estimated 3 million Americans living with IBD, and the many more who have experienced bouts of gut inflammation from infections or other causes, this research underscores the importance of proactive monitoring. Studies indicate that people with long-standing ulcerative colitis have a roughly 2% risk of colorectal cancer per decade of disease duration, according to published gastroenterology literature.
Healthcare professionals already recommend that IBD patients undergo regular colonoscopies to screen for dysplasia (precancerous cell changes). This new research adds biological weight to those recommendations and may eventually lead to updated guidelines that account for epigenetic risk factors alongside traditional inflammatory markers.
While these findings are currently based on animal models, researchers at the Broad Institute are working to determine whether similar epigenetic memory patterns appear in human colon tissue. The study is part of the broader Cancer Grand Challenges consortium PROSPECT, supported by the NCI, Cancer Research UK, and the French National Cancer Institute.
Supporting Gut Health to Reduce Chronic Inflammation
While molecular therapeutics targeting AP-1 remain on the research horizon, evidence-based lifestyle approaches may help reduce chronic gut inflammation and support overall gastrointestinal health. Research suggests the following may be beneficial:
- Anti-inflammatory diet: Mediterranean-style eating patterns rich in vegetables, legumes, olive oil, and omega-3 fatty acids have been associated with lower markers of systemic inflammation in multiple large observational studies.
- Fermented foods and probiotics: Emerging research points to connections between the gut microbiome and inflammatory regulation, suggesting that a diverse microbiome may play a protective role.
- Fiber intake: High dietary fiber has been consistently linked to reduced colorectal cancer risk in large cohort studies, with the World Health Organization noting that whole grain intake is associated with lower colorectal cancer incidence.
- Physical activity: Regular moderate exercise has been shown to reduce systemic inflammatory markers and is associated with decreased colorectal cancer risk in epidemiological research.
- Avoiding smoking and excess alcohol: Both are established risk factors for colorectal cancer and are known to promote gut inflammation.
If you have been diagnosed with IBD or have a history of chronic gut inflammation, consult your gastroenterologist or healthcare provider about appropriate screening timelines and any personalized risk-reduction strategies.
The Bottom Line
This groundbreaking NIH-funded study from the Broad Institute of MIT and Harvard has illuminated a compelling new pathway through which chronic gut inflammation may leave a long-lasting molecular legacy — one encoded in the epigenomes of gut stem cells and capable of accelerating cancer development long after symptoms resolve. The discovery of AP-1 transcription factors as a key mediator offers a potential target for both early detection and future therapeutic intervention.
Published in Nature (DOI: 10.1038/s41586-026-10258-4), this research marks a meaningful step forward in understanding one of the most preventable yet deadly cancers. As science continues to decode the complex dialogue between inflammation, epigenetics, and cancer, the message for patients and clinicians alike is clear: gut health matters — not just today, but for years to come.
Disclosure: It is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.